

# Creatine as an antioxidant

Piero Sestili · C. Martinelli · E. Colombo ·  
E. Barbieri · L. Potenza · S. Sartini ·  
C. Fimognari

Received: 10 July 2010 / Accepted: 30 November 2010  
© Springer-Verlag 2011

**Abstract** Creatine monohydrate (Cr), the most diffuse supplement in the sports industry, is receiving greater attention because of its beneficial effects in a wide number of human degenerative diseases and conditions. These effects can be barely explained on the basis of the sole ergogenic role of the Cr/CrP system. Indeed, a wide number of research articles indicate that Cr is capable of exerting multiple, non-energy related, effects on diverse and relevant cellular targets. Among these effects, the antioxidant activity of Cr emerges as an additional mechanism which is likely to play a supportive role in the Cr-cytoprotection paradigm.

**Keywords** Creatine · Oxidative stress · Antioxidant · Cytotoxicity · Genotoxicity · Differentiation

## Introduction

Over the past decade the use of creatine monohydrate (Cr) for therapeutic and chemopreventive purposes has received increasing attention (Gualano et al. 2009). The beneficial

effects of Cr supplementation have been reported for a large number of muscular, neurological and cardiovascular diseases (Sharov et al. 1987; Gordon et al. 1995; Holtzman et al. 1999; Matthews et al. 1999; Neubauer et al. 1999; Felber et al. 2000; Vorgerd et al. 2000; Mazzini et al. 2001; Stout et al. 2001; Wyss and Schulze 2002; Tarnopolsky et al. 2004; Tarnopolsky 2007) as well as in sarcopenia and ageing (Bender et al. 2007; Tarnopolsky 2007; Tarnopolsky and Safdar 2008). The benefits of Cr have been generally attributed to the Cr-induced buffering of cellular ATP levels, a pronounced decrease of which would otherwise lead to the accumulation of intracellular  $Ca^{2+}$ , formation of reactive oxygen species (ROS) and tissue oxidative damage (Persky and Brazeau 2001). Indeed, most of these pathologies recognize multiple aetiological factors among which the detrimental role of oxidative stress has been stably recognized (Gilgun-Sherki et al. 2004; Kovacic and Thurn 2005).

In 2002 Lawler (Lawler et al. 2002) demonstrated that Cr acts as a direct scavenger of radical species in an acellular setting. Thereafter, studies from our laboratory as well as from other groups have been devoted to understanding whether Cr may exert antioxidant effects in cultured mammalian cells (a summary of the studies dealing with the antioxidant or antioxidant-like activity of Cr is presented in Table 1). The overall aim of this article was to review these studies and their biological, nutritional and therapeutic implications.

## Direct antioxidant effect of Cr

The first evidence for an “antioxidant-like” activity of Cr was reported by Matthews et al. (1998). In this study, the authors provided evidence that oral Cr supplementation

---

P. Sestili (✉) · C. Martinelli · E. Colombo · E. Barbieri ·  
L. Potenza  
Dipartimento di Scienze Biomolecolari, Università degli Studi di  
Urbino “Carlo Bo”, Via Saffi, 2, 61029 Urbino, Italy  
e-mail: piero.sestili@uniurb.it

S. Sartini  
Dipartimento di Scienze della Terra, della Vita e dell’Ambiente  
(DiSTeVA), Università degli Studi di Urbino “Carlo Bo”,  
Campus Scientifico, 61029 Urbino, Italy

C. Fimognari  
Dipartimento di Farmacologia, Università degli Studi di  
Bologna, Via Irnerio 48, 40126 Bologna, Italy

**Table 1** The antioxidant or “antioxidant-like” effects of Cr

Reference	Effect
Matthews et al. (1998)	Cr supplementation protects rats from nitropropionic acid-intoxication
Lawler et al. (2002)	Direct antioxidant effect of Cr in acellular systems
Berneburg et al. (2005)	Cr protects from induction of the common deletion, a mtDNA mutation marker, generated in normal human fibroblast by repetitive UV-A irradiation through an energy-dependent mechanism
Lenz et al. (2005)	Protection of mtDNA against UV- and oxidative stress-induced damage in human keratinocytes
Meyer et al. (2006) Santiago et al. (2008)	Cr prevents mitochondrial ROS formation through the preservation of mtCK activity
Sestili et al. (2006)	Cr affords cytoprotection in oxidatively injured cultured mammalian cells <i>via</i> direct antioxidant activity
Guidi et al. (2008)	Cr protects against oxidative mtDNA damage in HUVEC cells
Rakpongsiri and Sawangkoon (2008)	The combination of Cr supplementation, oestrogen replacement and combined exercise training ameliorates the cardiac reserve function and antioxidant reservation against oxidative stress in oestrogen-deficient hamsters
Bender et al. (2007)	Improved health and survival in Cr-supplemented mice
Fimognari et al. (2009)	Creatine protects against oxidative RNA damage
Rambo et al. (2009)	Attenuation of seizures and oxidative damage in pentilentrazol-intoxicated rats
Sestili et al. (2009)	Cr supplementation prevents the inhibition of myogenic differentiation in oxidatively injured C2C12 murine myoblasts
Hosamani et al. (2010)	Attenuation of rotenone-induced mitochondrial oxidative damage and neurotoxicity in <i>Drosophila melanogaster</i> supplemented with Cr
Young et al. (2010)	Induction of the antioxidant enzymes peroxiredoxin-4, a type 2 peroxiredoxin-4 reductase and thioredoxin dependent peroxide reductase in C2C12 cells

was capable of protecting rats from nitropropionic acid-intoxication (an animal model of Huntington’s disease). Similar protective effects are granted by some well-established antioxidants such as *N*-acetylcysteine. Indeed, production of ROS and reactive nitrogen species represents an aetiologically relevant event in this model of Huntington’s disease. The same authors found that oral Cr supplementation was capable of significantly attenuating the hydroxyl radical and peroxynitrite generation in nitropropionic acid-intoxicated rats. However, this latter effect was not ascribed to a direct scavenging activity of Cr, but rather to an energy-related mechanism, namely the amelioration of intracellular calcium buffering in target cells ensuing the prevention of free radical production by mitochondria. Few years later, Lawler et al. (2002) was the first to test the hypothesis that Cr was capable of acting as a radical scavenger using a well-controlled acellular experimental setting. This study showed that Cr—unlike Cr phosphate (CrP)—was capable of scavenging charged radicals such as the 2,2′-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid radical, superoxide anion and peroxynitrite; by contrast, no significant quenching effect was observed on the non radical oxidants H<sub>2</sub>O<sub>2</sub> and tert-butyl-hydroperoxide (tBOOH). Unfortunately, the effect of Cr on toxicologically relevant H<sub>2</sub>O<sub>2</sub>- or tBOOH-derived radicals (hydroxyl and alkoxy radicals, respectively (Guidarelli et al. 1995)), was not specifically investigated. It was also suggested that the antioxidant activity might relate to some

of the effects observed *in vivo* upon Cr supplementation in athletes, such as the diminished muscle fatigue.

Although this study clearly demonstrated the scavenging capacity of Cr, it did not investigate whether Cr acted as an antioxidant in cellular experimental systems.

This prompted us to address this issue (Sestili et al. 2006). Following Cr pre-loading, three mammalian cell lines—U937 (human promonocytoid), C2C12 (murine mioblasts) and HUVEC (human umbilical vein endothelial cells)—all expressing Cr transporters were treated with a panel of oxidative stressors capable of generating toxic radical species *in vivo*, namely H<sub>2</sub>O<sub>2</sub>, tBOOH and peroxynitrite, and various end-points indicative of antioxidant activity were determined. The three stressors were given to cells at concentrations resulting in mild to extensive cytotoxicity. Notably, in living cells H<sub>2</sub>O<sub>2</sub> and tBOOH undergo Fenton reaction and form hydroxyl and alkoxy radicals, respectively (Guidarelli et al. 1995). Cr pre-loading (concentrations ranging from 0.1 to 10 mM) was found to be mildly but significantly cytoprotective in all the conditions tested; this effect was dose-related (Fig. 1a–c shows the effect of Cr in these three cell lines) and similar to that granted by the hydrophilic vitamin E analogue trolox, used as a reference antioxidant (Azzi et al. 2004). Morphological and ultrastructural analysis at the light and transmission electron microscope confirmed these results. Interestingly, Cr cytoprotection was fully prevented by adding the Cr uptake inhibitor  $\beta$ -guanidinopropionic acid


(GPA) (Otten et al. 1986) to the Cr pre-incubation milieu, indicating that the intracellular fraction of Cr is responsible for the observed protective effects. Cr pre-loading was unable to increase the activity of the two main antioxidant detoxifying enzymes, namely catalase and glutathione peroxidase, suggesting that the effects of Cr were not mediated by an increased activity of these two enzymes. In an opposite but converging direction, catalase and glutathione-depleted U937 cells were—as expected—sensitized to H<sub>2</sub>O<sub>2</sub> toxicity but still responsive to Cr cytoprotection and to an extent identical to that found in normal, undepleted cells. Interestingly, Cr pre-loading—similarly to trolox—attenuated the decrease of non protein sulphhydryls (NPSH, of which GSH represents  $\geq 90\%$ ) typically induced by either H<sub>2</sub>O<sub>2</sub> or tBOOH. In addition, the levels of extracellular H<sub>2</sub>O<sub>2</sub> found at the end of treatments in the supernatants of U937 cells were lower in Cr pre-loaded- as compared with unsupplemented- samples. Both these effects (sparing of NPSH and reduction of the extracellular levels of H<sub>2</sub>O<sub>2</sub>) might depend on (1) increased availability of NPSH, (2) the overall amelioration of the antioxidant cellular systems, (3) the prevention of the generation or (4) on direct scavenging of toxic ROS derived from the oxidative stressors. As to the first two hypotheses, they seemed unlikely since Cr, as discussed above, did not increase the activity of catalase or glutathione peroxidase, nor affected the cellular constitutive levels of NPSH. Thus, it is plausible that the protective effects discussed so far depend on the direct antioxidant activity which, evidently, takes place also in cellular systems provided that intracellular free Cr reaches a “threshold” level attainable upon adequate supplementation. As to the mechanism underlying the antioxidant activity, the possibility that Cr might act as an iron chelator (Azzi et al. 2004; Sestili et al. 2007) capable of blocking the ROS-generating Fenton reaction was also ruled out. Thus, Cr seemed to act as a scavenger of radical species. The similarity between Cr and trolox or other reference radical scavengers (Sestili et al. 2006) found in our experimental setting further supports this concept. However, these reference antioxidants do not exhibit a character peculiar of Cr, i.e. its fundamental role in cellular energy status. As discussed earlier, and as proposed by various authors in studies dealing with Cr-protective effects, the energetic role of Cr might represent *per se* a mechanism capable of rendering cells more resistant to oxidative stress. To understand whether Cr cytoprotection might depend on an antioxidant or an energy-related mechanism, the intracellular levels of free Cr and of CrP following pre-loading stages identical to those used in cytotoxicity experiments were determined by means of HPLC. The three cell lines (U937, HUVEC and C2C12) accumulated different levels of Cr as well as of CrP, but the protective effects appeared only when free Cr levels

significantly increased. In particular, among the three cell lines tested, U937 cells rapidly accumulated fairly high levels of free Cr in the absence of a corresponding increase in CrP. Despite this behaviour, U937 cells were rapidly and significantly protected by Cr supplementation. Furthermore, a linear correlation irrespective of cell type was found between the free Cr intracellular levels and the degree of cytoprotection (Fig. 1d), while no correlation was found in the case of CrP levels. Thus, the effects observed in this oxidative stress paradigm are clearly related to the intracellular availability of free Cr rather than of its phosphorylated form.

As to the identification of the oxidation product(s) of Cr, mass spectrometry analyses of solutions containing Cr and H<sub>2</sub>O<sub>2</sub> or peroxyntrite as well as of lysates from Cr-supplemented cells treated with the aforementioned oxidants showed the formation of putative oxidation products with MW at 136 and 150 (Sestili et al. 2006) whose structures have still to be better defined by means of infrared spectroscopy and mass–mass spectrometry.

### Protective activity of Cr on oxidatively injured mitochondrial (mt) DNA

Mitochondria and mtDNA represent important targets for oxidative damage. Indeed, mtDNA mutations have recently been reported as being an aetiological factor in oxidative stress-related disorders (Copeland 2010) including cardiovascular diseases and inherited or acquired neurodegenerative disorders, several types of tumours, mitochondrial myopathies and the normal ageing process. Mitochondrially targeted antioxidants have been proposed as valuable tools to protect mitochondria from pathologically and toxicologically relevant alterations (Reddy 2008). Due to its mitochondrial tropism (Walzel et al. 2002), we extended our studies to investigate the possible protective effects of Cr on oxidatively damaged mtDNA from HUVEC cells. Cells were pre-incubated for 24 h with or without Cr and then treated for 30 min with 200  $\mu$ M H<sub>2</sub>O<sub>2</sub>; cells were then grown for up to 72 h and assayed at specific time points for viability (again, Cr was cytoprotective) and nuclear and mtDNA damage (Guidi et al. 2008). This latter endpoint was determined using a two-step strategy based on a Long PCR and a REAL-TIME PCR: importantly, this assay allows monitoring of the integrity of mtDNA directly from total cellular DNA avoiding processes which can increase base oxidation such as isolation of mitochondria or separate mtDNA purification steps (Guidi et al. 2008). Results obtained showed that Cr significantly protected mtDNA from oxidative damage, with respect to H<sub>2</sub>O<sub>2</sub>-treated, Cr-unsupplemented samples. The effect of Cr on mtDNA, as assayed immediately after oxidative challenge, was dose



**Fig. 1** Effect of Cr pre-loading on oxidant-induced cytotoxicity in cultured mammalian cells. U937 (a), HUVEC (b) or C2C12 (c) cells were pre-incubated for 1 h (U937) or 24 h (HUVEC and C2C12) with increasing concentrations of Cr and then treated for 1 h with 0.3 (U937), 0.075 (HUVEC) or 0.2 mM (C2C12)  $H_2O_2$ . Cell survival was determined after 48 h of growth in fresh, Cr- and  $H_2O_2$ - free culture medium using the trypan blue exclusion assay. Results represent the

means  $\pm$  SEM from five to eight separate experiments. \* $p < 0.01$  and \*\* $p < 0.005$  (unpaired  $t$  test) compared with Cr-unsupplemented cells. **d** Correlation plot between the survival data shown in panels a, b and c and the levels of intracellular Cr determined (HPLC) in parallel cell samples immediately before oxidative challenge. Key: U937 cells, circles/dotted line; HUVEC, triangles/striped line; C2C12, squares/solid line

dependent in the 3–10 mM range; concentrations lower than 3 mM were ineffective. Moreover, the protection afforded by 10 mM Cr was significant up to 24-h repair periods, while no significant difference with Cr unsupplemented cells could be seen at 48 h. It is worth noting that Cr effects were more pronounced at very early post-challenge times: this suggests that Cr prevents the induction of the lesions—possibly *via* direct antioxidant activity—rather than acting after and/or downstream their formation. This notion, i.e. the prevalence of a non-metabolic mechanism, is indirectly supported by the observation reported by Guidi et al. (2008) that in an acellular setting Cr reduced the extent of  $H_2O_2$ -induced lesions on 600 bp linear or circular DNA.

Thus, Cr supplementation may play an important role in mt genome stability in that it could normalize mitochondrial mutagenesis and prevent its functional consequences such as the decrease of oxygen consumption, mitochondrial membrane potential, ATP content and cell survival. These effects might be clinically relevant in preventing or ameliorating a wide range of pathologies where mitochondrial oxidative damage is known to play an aetiological role. Also, protection of mtDNA damage might represent one of

the mechanisms contributing to the improved health and survival recently reported by Bender et al. (2007) in mice receiving a Cr-enriched diet.

### Protective activity of Cr on oxidatively injured cellular RNA

RNAs are the only known molecules which possess the double property of being depository of genetic information, like DNA, and of displaying catalytic activities, like protein enzymes. RNA molecules intervene in all steps of gene expression and in many other biological activities (Hermann and Westhof 2000).

RNA and DNA are chemically similar. However, their structure and function are different. The ability of xenobiotics to target DNA has been extensively studied. RNA could have enhanced potential for attack by xenobiotics because it possesses some characteristics (largely single-stranded, more abundant than DNA, subcellular distribution in close proximity of mitochondria, etc.) making it theoretically more susceptible to chemical insults than DNA (Bregon and Sarasin 2005). While less lethal than

mutations in the genome, such non-acutely lethal insults to cells have been recently associated with underlying mechanisms of several human diseases, especially chronic degeneration. A significant loss of RNA integrity has been demonstrated in advanced human atherosclerotic plaques (Martinet et al. 2004, 2005), several neurodegenerative diseases including Alzheimer disease, Parkinson disease, dementia with Lewy bodies, and prion diseases (Nunomura et al. 2009). Of note, RNA damage may also affect the balance between protein degradation and synthesis and repair-regeneration processes in skeletal muscles which ultimately determines total muscle mass and therefore sarcopenia (Malatesta et al. 2010; Tateyama et al. 2003; Tanaka et al. 2007; Hofer et al. 2008; Nunomura et al. 2009).

RNA damage can be related to the exposure to particular xenobiotics: different compounds able to damage RNA have been identified through an innovative automated high-throughput approach (Fimognari et al. 2008).

By using this approach, the RNA-damaging activities of different compounds have been demonstrated:  $H_2O_2$ ; doxorubicin, which acts as both an alkylating and an oxidizing agent; spermine, one of the few NO-donors releasing authentic NO and ROS; *S*-nitroso-*N*-acetylpenicillamine (SNAP), a donor of NO (Fimognari et al. 2008).

In an attempt to envisage the possible use of Cr in the prevention or amelioration of a wide range of human diseases where RNA damage may play an etiological role, a study analysed the effects of Cr in counterstaining the RNA-damaging activity of the earlier reported compounds.

Interestingly, Cr was able to reduce the RNA damage induced by two of those toxic agents ( $H_2O_2$  and doxorubicin), while it lacked activity in counterstaining the RNA damage induced by the NO donors spermine and SNAP. Its inhibitory activity against  $H_2O_2$ -induced RNA damage was dependent on its capacity to directly scavenge free radicals (Fimognari et al. 2009).

The mechanism for Cr protection against RNA damage induced by doxorubicin is more complex. The Cr kinase/CrP system is an important target of doxorubicin toxicity (Tokarska-Schlattner et al. 2002). Doxorubicin was able to oxidize creatine kinase thiols (direct effect) and generate ROS that contribute to further damage (indirect effect) (Weinstein et al. 2000). The protective effect of Cr against the RNA damaging activity of doxorubicin could be partially attributed to a build-up of CrP stores, which increase the efficiency of ATP regeneration. The radical scavenging activity of Cr also points to the role of free Cr as an antioxidant and suggests that the effect on RNA damage induced by doxorubicin might represent an additive, important mechanism contributing to its cytoprotective activity in doxorubicin-intoxicated cells (Fimognari et al. 2009). On the whole, these studies indicate that the


beneficial effects of Cr supplementation may derive, beyond from its contribution to cellular energetics, also from its ability to protect a critical target such as RNA from oxidative attack.

### Antioxidant activity of Cr in differentiating murine myoblasts and chick embryo neuroblasts

It is well known that ROS—when their level exceeds the cellular antioxidant capacity—not only induce cell death in target tissues, but also affect/impair biologically and physiologically relevant processes. With regard to skeletal muscle, oxidative stress profoundly affects the proliferation/differentiation balance of satellite-derived cells and myoblasts (Langen et al. 2002) and promotes the loss of mature myofibers (Buck and Chojkier 1996). Notably, oxidative stress is known to play a concausal and detrimental role in a variety of multifactorial muscular pathologies characterized by proliferation/differentiation imbalance such as Duchenne dystrophy (Messina et al. 2006), myotonic dystrophy (Toscano et al. 2005), sarcopenia (Fulle et al. 2004) and muscle repair. Counteracting the deleterious effects of ROS in these situations is a clinically advisable goal which in principle could be attained administering specific antioxidants through the diet. However, not all the antioxidants are characterized by favourable pharmacokinetics with regard to muscle tissues; on the contrary, Cr fulfils the requisites of a “nutritargeted” (“nutritargeting” means targeting nutrients to specific “target” tissues (Biesalski and Tinz 2008)) muscular antioxidant since it is highly taken up, concentrated and durably retained by muscle cells (Wyss and Kaddurah-Daouk 2000). At this level, Cr exerts also a number of positive effects such as the increased expression of selected myogenic transcriptional regulators (MRFs)- and of IGF-1-mRNAs (Louis et al. 2004; Deldicque et al. 2007) and augmentation of the CrP stores (Alfieri et al. 2006). Based on these premises, we investigated whether Cr prevented, in comparison with established antioxidants, the arrest of the myogenic process in C2C12 myoblasts exposed to oxidative stress at an early differentiation time (Sestili et al. 2009). Differentiating cultures were pre-loaded with Cr for 24 h, treated with  $H_2O_2$  given as a bolus for 1 h and then grown for up to 5 days to allow progression and completion of the myogenic program. In keeping with previous observations,  $H_2O_2$  was mildly cytotoxic to differentiating C2C12 and markedly hampered the progression of the differentiative task. Interestingly, Cr significantly and dose-dependently attenuated the cytotoxic impact of  $H_2O_2$ , as assessed by means of MTT, trypan blue and total protein determination assays; pre-loading with trolox behaved similarly. Oxidative stress caused a significant decrease of



Cr and CrP levels in Cr-unsupplemented cultures at 48 h post-treatment, as compared with unintoxicated controls. On the contrary, Cr-supplementation resulted in a three to fourfold increase in Cr and CrP levels at the  $H_2O_2$  treatment stage: notably, these levels, although decreasing over time, were still higher at 48 h post-oxidative challenge, as compared with untreated, unsupplemented cells. Replacing Cr with trolox did not affect the basal Cr or CrP levels, while slightly preventing their decrease in Cr-unsupplemented cells 48 h post  $H_2O_2$  challenge. As to ATP and NPSH levels, both Cr and trolox attenuated the depletion observed at 48 and 0 h after  $H_2O_2$  treatment, respectively. Addition of GPA to Cr-enriched media during the pre-loading stage prevented either the intracellular accumulation of Cr or its protective effects. Thus, both Cr and trolox were equally capable of rescuing cells from the cytotoxic activity of the oxidant and, at the concentrations used, seemed to exert a similar antioxidant activity. However, Cr effects were markedly different as compared with those of trolox in terms of the rescue of the differentiative capacity of intoxicated cultures.  $H_2O_2$  treatment abolished the progression of C2C12 myogenic differentiation as assessed by means of biochemical, morphological (Fig. 2), ultrastructural and molecular analyses; a negligible rescue was afforded by trolox while Cr pre-loading restored almost completely the ability of C2C12 to execute the myogenic program. Indeed, Cr-enriched cultures, unlike trolox-enriched ones, were characterized by the presence of a percentage of developing or mature myotubes (as determined by means of light, transmission and scanning electron microscopy 2 and 4 days post-challenge) similar to that of controls; proteomic analysis of Cr cultures in the course of differentiation showed electropherograms indistinguishable from those of control, unintoxicated cells: in particular, annexin 1, gelsolin and ATP synthase D-chain, whose levels were low to undetectable in  $H_2O_2$ -treated cells and that increased in control cultures according to their differentiation (Scholz and Hinssen 1995; Tannu et al. 2004), were normally expressed in Cr pre-loaded,  $H_2O_2$ -treated cells. Similar results were obtained with regard to myosin heavy chain, a reliable and typical marker of muscle differentiation (Ardite et al. 2004). Transmission electron microscopy also indicated that—48 h after treatment— $H_2O_2$ -intoxicated cells showed marked degeneration and loss of mitochondria, suggesting that these organelles might represent a particularly relevant target in this toxicity paradigm: again, this effect was prevented by Cr-priming, and not by trolox. Protection of mitochondria is of utmost importance with regard to muscle differentiation since it is well known that this process requires sustained mitochondrial activity and mitochondriogenesis (Rochard et al. 2000). It is likely that the rescue of mitochondria might also depend on the ability of Cr to reduce the extent of



**Fig. 2** Scanning electron micrographs of differentiating C2C12 myoblasts: the effect of oxidative challenge and of Cr supplementation. Cells were maintained for 24 h in differentiation medium in the absence or in the presence of 3 mM Cr; the medium was changed with fresh Cr-free medium and cultures were then treated for 1 h with 0.3 mM  $H_2O_2$ . Finally, cells were cultured for further 4 days in fresh Cr and  $H_2O_2$ -free medium. Micrographs were taken on the third and fifth day of differentiation. Bars 10  $\mu$ m

$H_2O_2$ -induced mtDNA damage, an effect which has been demonstrated in HUVEC cells and that is also being investigated in oxidatively injured, differentiating C2C12 cells. In this regard we found that, 48 h after the oxidative insult, differentiating C2C12 cells pre-loaded with Cr showed levels of mtDNA copies (mtDNA/nDNA ratio) higher than those from  $H_2O_2$ -treated, Cr-unsupplemented cells and similar to control cultures (unpublished observations).

Other Cr-induced effects independent from antioxidant mechanisms but relevant to the myogenic ability and its resistance to oxidative stress have been identified. Cr pre-loading up-regulated the mRNA expression of IGF-1 and of several MRFs such as MRF4 and myogenin 24 and 48 h after serum deprivation, supporting the hypothesis that a threshold level of MRF expression is reached earlier in the presence of Cr (Louis et al. 2004). Up-regulation of these targets was quantitatively similar to that observed previously (Louis

et al. 2004; Deldicque et al. 2007) and is likely to play a pivotal role in the observed hypertrophic response of Cr-primed differentiating C2C12 cells. H<sub>2</sub>O<sub>2</sub> treatment significantly reduced the expression level of IGF-1, MRF4 and myogenin, as compared with untreated cells; IGF-1 seems to be particularly sensitive to oxidative challenge. Interestingly, Cr pre-loading prevented these effects: indeed, 3 days after serum deprivation and 2 after oxidative challenge Cr-primed H<sub>2</sub>O<sub>2</sub>-injured cells expressed levels identical (MyoD and myogenin) to, or even higher (IGF-1 and MRF4) than those of control, Cr-unsupplemented cells. Again, the effects induced by trolox were far different than those elicited by Cr: indeed, it lacked the capacity of stimulating the expression of either IGF-1 or of the other MRFs.

It is also worth noting that it has been recently reported that IGF-1 induces a strong oxidant-resistant phenotype, which reflects the inhibition of ROS production in the cytosolic and mitochondrial compartments in mesangial cells (Kang et al. 2003; Yang et al. 2005). This additional mechanism might contribute to render cells more resistant to oxidative stress and its consequences. Further studies in this direction will be needed to fully establish this hypothesis.

As to non muscular tissues, recent experimental reports suggest that Cr might play an important role in correct CNS neuron differentiation and function. As an example, Cr can be exocytotically released by neurons as a cotransmitter (Almeida et al. 2006) and modulate GABA<sub>A</sub> receptors exerting either inhibitory (De Deyn and Macdonald 1990) or excitatory (Koga et al. 2005) actions. It is worth considering that GABA receptor activity plays important roles during brain development participating in neuron differentiation, migration, dendritic maturation and modelling of neuronal circuitry (for an extensive review, see Represa and Ben-Ari 2005). Moreover, *in vitro* Cr supplementation was seen to readdress neuron differentiation toward GABA-ergic phenotype in striatal (Andres et al. 2005) and spinal cord cell cultures (Ducray et al. 2007). In spite of these evidences, during—and up to the later stages of—pregnancy, endogenous Cr synthesis in the developing brain is very limited in such a way that maternal Cr is the main source for most of foetal life (Braissant et al. 2007; Ireland et al. 2009). As a consequence, developing CNS is seriously exposed to the risk of Cr deficiency in case of premature birth or placental insufficiency, a fact that suggests that Cr supplementation could be important in these situations. Also, pro-differentiative and antioxidant activities of Cr on CNS could assume particular interest because there is mounting evidence that oxidative damage to vital cellular targets contributes to the pathogenesis of brain injury in both the immature and mature nervous system (McQuillen and Ferriero 2004). After perinatal ischemic injury from various stimuli, it is believed that the infant

brain experiences a cascade of toxic events involving energy failure, glutamate release, activation of NMDA receptors, calcium influx and formation of NO by nNOS (Vexler and Ferriero 2001). These events result in mitochondrial dysfunction and leakage of O<sub>2</sub>, which is dismutated to more toxic reactive species such as hydrogen peroxide and hydroxyl radical.

Since, to the best of our knowledge, there is no study directly aimed at investigating whether Cr protects differentiating neuroblasts from oxidative attack, we set out a study similar to that carried out in differentiating C2C12 myoblasts (unpublished observations). For this purpose, primary cultures of neuroblasts from spinal cords of 7-day-old chick embryos were prepared and grown for 24 h; cultures were then maintained in the absence or in the presence of 5, 10 or 20 mM Cr for 24 h, acutely challenged with a bolus of H<sub>2</sub>O<sub>2</sub> (5–30 μM for 40 min) and then cultured for up to further 4 days to monitor their viability and NPSH intracellular levels; neurite length and voltage gated ion currents (by whole-cell patch-clamp) were parallelly monitored and taken as indexes of morphological or functional differentiation, respectively.

As expected, oxidative treatment caused an acute reduction of NPSH levels and a marked, dose-related loss of viability (as assessed by means of MTT and cell counting). These effects, which are typically induced by H<sub>2</sub>O<sub>2</sub> could be prevented either by the reference antioxidant trolox or by 10 mM Cr. At the differentiative level, neuroblasts surviving the H<sub>2</sub>O<sub>2</sub> insult displayed profound neurite structural damages which reflect their difficulty to continue a normal differentiative task while notably, in the case of Cr pre-loaded cells, neurites were morphologically indistinguishable from those of unintoxicated controls. Trolox afforded a slightly lower protection to neurite elongation and branching, as compared with Cr. As to the assessment of the functional competence of differentiating neuroblasts, a more complex interpretation of the electrophysiological results has to be drawn. Indeed, only cells with a well-preserved membrane integrity are eligible for whole-cell patch clamp assays: as a consequence, among oxidative-stressed cells only those capable of maintaining their integrity during the procedure could be scored in such a way that the results obtained might represent some underestimation of the overall and actual suffering of H<sub>2</sub>O<sub>2</sub>-injured cultures. According to this latter notion, H<sub>2</sub>O<sub>2</sub>-treated cells did not show significant electrophysiological differences (Na<sup>+</sup> and K<sup>+</sup> voltage-gated currents) as compared with controls. On the contrary Cr-enriched cells, independently of H<sub>2</sub>O<sub>2</sub> intoxication showed, with respect to controls, a dose/time-dependent increase of Na<sup>+</sup> and K<sup>+</sup> voltage-gated current intensities during differentiation. Again, all the effects elicited by Cr were prevented by co-exposure with GPA.

### Other indirect effects possibly contributing to Cr antioxidant activity

Other non-scavenging effects of Cr that may anyhow contribute to increase cellular resistance to oxidative stress—or to critical situations where ROS are involved—have been reported. A recent study by Young et al. (2010), using an explorative NMR-based metabolomic and proteomic approach, demonstrates that in mature murine C2C12 myotubes Cr promotes an additional, indirect antioxidant effect, i.e. the up-regulation of one of the cellular antioxidative systems, namely the thiol redox system, which consists of the glutathione and thioredoxin pathways. Two thioredoxin reductases situated in the mitochondria and cytoplasm, respectively, were increased in Cr-treated cells: peroxiredoxin-4, a type 2 peroxiredoxin, and thioredoxin-dependent peroxide reductase. Up-regulation of these enzymes might effectively contribute to some of the protective effects discussed throughout this article. Extending this investigation to other cell types will be important in order to understand the relative contribution of direct and indirect scavenging in Cr protection from oxidative stress.


Meyer et al. (2006) reported that in hyperglycemic conditions, mt creatine kinase (mtCK) activity—supported by an availability of Cr resulting in adequate CrP/Cr ratios—prevents mitochondrial ROS formation through the ADP-cycling system and thus identified an antioxidant-like role for mtCK unrelated to the direct scavenging capacity of Cr. Beneficial effects of Cr have been observed in keratinocytes exposed to UV rays (whose toxicity depends in part on intracellular ROS formation) and H<sub>2</sub>O<sub>2</sub>. In this study, the authors (Lenz et al. 2005) ascribed this activity to a protective effect of Cr on CK oxidant-induced inactivation *via* a non-antioxidant mechanism, but rather *via* an energy related one. Accordingly, Berneburg et al. (2005) had previously demonstrated that 1 mM Cr, by normalizing

the cell's energy status, completely abolished induction of the common deletion, a mtDNA mutation marker, generated in normal human fibroblast by repetitive UV-A irradiation.

### Conclusion

Cr is capable of exerting mild direct antioxidant activity in cultured mammalian cells acutely injured with an array of different ROS generating compounds. This activity, on a molar basis, is far lower than that of many other antioxidants of natural origin: for example, many polyphenols from plants act as antioxidants in the nanomolar to micromolar range, while Cr scavenging activity becomes apparent above a threshold level which, importantly, is similar to that attainable in plasma upon oral Cr supplementation in humans (1–2 mM). However, Cr is a “physiologically on-board” ubiquitous molecule and, as a consequence, its pharmacokinetic—especially with regard to specific tissues—is far better than that of many plant antioxidants and may greatly improve its actual efficacy. Of note, Cr also protects from oxidative damage two distinct and critical cellular targets, namely mtDNA and RNA. Furthermore and differently from established antioxidants, Cr has been shown to promote other relevant effects which contribute to rescue cell viability and function under oxidative stressing conditions, particularly in the case of differentiating myoblasts (Fig. 3). In this situation Cr (1) preserves the integrity of mitochondria allowing adequate mitochondriogenesis, probably *via* its organelle-directed antioxidant activity (Guidi et al. 2008) (2) affords a significant sparing of intracellular thiols content (3) protects RNA from oxidative damage in a condition requiring a robust mRNA utilization (4) increases the expression of selected MRFs and of IGF-1 mRNAs and (5) augments the CrP stores, thus ameliorating cellular energy charge. Only

**Fig. 3** Toxicologically relevant targets triggered by oxidative stress and preserved or ameliorated by Cr supplementation in differentiating C2C12 myoblasts. *MRF* muscle regulatory factors





the first three of these effects are likely to be mediated by the antioxidant capacity of Cr; the other two effects are a peculiar to Cr and independent of its antioxidant capacity, as indirectly suggested by the fact that trolox—which only acts as a ROS scavenger—increases neither MRFs and IGF-1 nor CrP pools.

These observations lend further support to the concept that the beneficial effects of Cr that are being observed at the therapeutic and preventive levels (Sipila et al. 1981; Osbakken et al. 1992; Gordon et al. 1995; Heinanen et al. 1999; Matthews et al. 1999; Vorgerd et al. 2000; Hespel et al. 2001; Mazzini et al. 2001; Stout et al. 2001; Witte et al. 2001; Tarnopolsky et al. 2004; Hansen et al. 2006; Kuethe et al. 2006) may not depend exclusively on the role of Cr in cellular energetics, but rather on multiple positive interactions with diverse cellular targets (Lawler et al. 2002; Louis et al. 2004; Lenz et al. 2005; Alfieri et al. 2006; Olsen et al. 2006; Sestili et al. 2006; Bender et al. 2007; Brosnan et al. 2007; Ducray et al. 2007; Rodriguez et al. 2007; Guidi et al. 2008; Oliveira et al. 2008). The comprehension of Cr pleiotropism is an emerging issue in research literature, and the results in this direction might be important to rationally interpret the role and exploit the therapeutic/preventive potential of Cr supplementation in specific situations.

The implications of this concept are manifold and raise clinical, nutritional and future research issues. As discussed previously, muscle inflammation and a variety of muscular disorders are complicated by both persisting oxidative stress and impairment of the tissue repair capacity (Vorgerd et al. 2000; Hespel et al. 2001; Mazzini et al. 2001; Stout et al. 2001; Fulle et al. 2004; Tarnopolsky et al. 2004; Hansen et al. 2006). The complex antioxidant capacity of Cr might then help to better understand the mechanisms whereby its oral supplementation is somehow beneficial in the above muscle and heart diseases as well as to lend support to its use in these situations.

In a different clinical perspective, the outcome of myoblast transplantation, a promising strategy for the therapy of muscular dystrophies and heart diseases, is affected by the poor survival of implanted myoblasts (Vilquin 2005). Since it has been proposed that oxidative stress contributes to this problem, Cr pre-implant loading of myoblasts might result in a better survival and differentiative efficiency of implanted cells, and better clinical outcomes of this procedure. Finally, the use of supplementary oral Cr intakes—as well as directly and rapidly driving Cr into injured muscles by means of medical devices such as hydroelectrophoresis (Brizzi et al. 2004)—should deserve consideration in post-trauma physical rehabilitation, i.e. a situation where better muscle regeneration is obviously advisable.

From a nutritional point of view, the antioxidant activity of Cr might help to understand and reappraise the benefits

arising from long-term Cr dietary supplementation, and support the advisability of elevating Cr levels not only in situations where meat consumption is obligatorily reduced (hypercholesterolemia, cardiovascular diseases, ageing, vegetarian diet), but also in specific groups (elderly, patients undergoing post-trauma rehabilitation, see also below) of omnivorous diet population. Indeed, plasma-Cr concentrations similar to those capable of eliciting the effects described herein (1–2 mM) can be achieved only through the adoption of specific oral supplementation regimens (Schedel et al. 1999). In this light, data discussed herein strengthen the rationale of “long-term dietary Cr supplementations” to gain a longer and healthier lifetime, as suggested by Bender et al. (2007) in a recent report showing that Cr improves health and survival of mice.

## References

- Alfieri RR, Bonelli MA, Cavazzoni A, Brigotti M, Fumarola C, Sestili P, Mozzoni P, De Palma G, Mutti A, Carnicelli D, Vacondio F, Silva C, Borghetti AF, Wheeler KP, Petronini PG (2006) Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress. *J Physiol* 576:391–401
- Almeida LS, Salomons GS, Hogenboom F, Jakobs C, Schoffemeer AN (2006) Exocytotic release of creatine in rat brain. *Synapse* (New York NY) 60:118–123
- Andres RH, Ducray AD, Huber AW, Perez-Bouza A, Krebs SH, Schlattner U, Seiler RW, Wallimann T, Widmer HR (2005) Effects of creatine treatment on survival and differentiation of GABA-ergic neurons in cultured striatal tissue. *J Neurochem* 95:33–45
- Ardite E, Barbera JA, Roca J, Fernandez-Checa JC (2004) Glutathione depletion impairs myogenic differentiation of murine skeletal muscle C2C12 cells through sustained NF-kappaB activation. *Am J Pathol* 165:719–728
- Azzi A, Davies KJ, Kelly F (2004) Free radical biology—terminology and critical thinking. *FEBS Lett* 558:3–6
- Bender A, Beckers J, Schneider I, Holter SM, Haack T, Ruthsatz T, Vogt-Weisenhorn DM, Becker L, Genius J, Rujescu D, Irmeler M, Mijalski T, Mader M, Quintanilla-Martinez L, Fuchs H, Gailus-Durner V, de Angelis MH, Wurst W, Schmidt J, Klopstock T (2007) Creatine improves health and survival of mice. *Neurobiol Aging* 29:1401–1411
- Berneburg M, Gremmel T, Kurten V, Schroeder P, Hertel I, von Mikecz A, Wild S, Chen M, Declercq L, Matsui M, Ruzicka T, Krutmann J (2005) Creatine supplementation normalizes mutagenesis of mitochondrial DNA as well as functional consequences. *J Invest Dermatol* 125:213–220
- Biesalski HK, Tinz J (2008) Nutritargeting. *Adv Food Nutr Res* 54:179–217
- Braissant O, Bachmann C, Henry H (2007) Expression and function of AGAT, GAMT and CT1 in the mammalian brain. *Sub-cell Biochem* 46:67–81
- Bregeon D, Sarasin A (2005) Hypothetical role of RNA damage avoidance in preventing human disease. *Mutat Res* 577:293–302
- Brizzi A, Giusti A, Giacchetti P, Stefanelli S, Provinciali L, Ceravolo MG (2004) A randomised controlled trial on the efficacy of hydroelectrophoresis in acute recurrences in chronic low back pain patients. *Europa Medicophysica* 40:303–309

- Brosnan ME, Edison EE, da Silva R, Brosnan JT (2007) New insights into creatine function and synthesis. *Adv Enzyme Regul* 47:252–260
- Buck M, Chojkier M (1996) Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. *EMBO J* 15:1753–1765
- Copeland WC (2010) The mitochondrial DNA polymerase in health and disease. *Subcell Biochem* 50:211–222
- De Deyn PP, Macdonald RL (1990) Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture. *Ann Neurol* 28:627–633
- Deldicque L, Theisen D, Bertrand L, Hespel P, Hue L, Francaux M (2007) Creatine enhances differentiation of myogenic C2C12 cells by activating both p38 and Akt/PKB pathways. *Am J Physiol Cell Physiol* 293:C1263–C1271
- Ducray AD, Schlappi JA, Qualls R, Andres RH, Seiler RW, Schlattner U, Wallimann T, Widmer HR (2007) Creatine treatment promotes differentiation of GABA-ergic neuronal precursors in cultured fetal rat spinal cord. *J Neurosci Res* 85:1863–1875
- Felber S, Skladal D, Wyss M, Kremser C, Koller A, Sperl W (2000) Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study. *Neurol Res* 22:145–150
- Fimognari C, Sestili P, Lenzi M, Bucchini A, Cantelli-Forti G, Hrelia P (2008) RNA as a new target for toxic and protective agents. *Mutat Res* 648:15–22
- Fimognari C, Sestili P, Lenzi M, Cantelli-Forti G, Hrelia P (2009) Protective effect of creatine against RNA damage. *Mutat Res* 670:59–67
- Fulle S, Protasi F, Di Tano G, Pietrangelo T, Beltramin A, Boncompagni S, Vecchiet L, Fano G (2004) The contribution of reactive oxygen species to sarcopenia and muscle ageing. *Exp Gerontol* 39:17–24
- Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. *J Neurol* 251:261–268
- Gordon A, Hultman E, Kaijser L, Kristjansson S, Rolf CJ, Nyquist O, Sylven C (1995) Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. *Cardiovasc Res* 30:413–418
- Gualano B, Artioli GG, Poortmans JR, Lancha Junior AH (2009) Exploring the therapeutic role of creatine supplementation. *Amino acids* 38:31–44
- Guidarelli A, Sestili P, Cossarizza A, Franceschi C, Cattabeni F, Cantoni O (1995) Evidence for dissimilar mechanisms of enhancement of inorganic and organic hydroperoxide cytotoxicity by L-histidine. *J Pharmacol Exp Ther* 275:1575–1582
- Guidi C, Potenza L, Sestili P, Martinelli C, Guescini M, Stocchi L, Zeppa S, Polidori E, Annibaldi G, Stocchi V (2008) Differential effect of creatine on oxidatively-injured mitochondrial and nuclear DNA. *Biochim Biophys Acta* 1780:16–26
- Hansen MJ, Gualano RC, Bozinovski S, Vlahos R, Anderson GP (2006) Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease). *Pharmacol Ther* 109:162–172
- Heinonen K, Nanto-Salonen K, Komu M, Erkintalo M, Alanen A, Heinonen OJ, Pulkki K, Nikoskelainen E, Sipilä I, Simell O (1999) Creatine corrects muscle 31P spectrum in gyrate atrophy with hyperornithinaemia. *Eur J Clin Invest* 29:1060–1065
- Hermann T, Westhof E (2000) Rational drug design and high-throughput techniques for RNA targets. *Comb Chem High Throughput Screen* 3:219–234
- Hespel P, Op't Eijnde B, Van Leemputte M, Urso B, Greenhaff PL, Labarque V, Dymarkowski S, Van Hecke P, Richter EA (2001) Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans. *J Physiol* 536:625–633
- Hofer T, Marzetti E, Xu J, Seo AY, Gulec S, Knutson MD, Leeuwenburgh C, Dupont-Versteegden EE (2008) Increased iron content and RNA oxidative damage in skeletal muscle with aging and disuse atrophy. *Exp Gerontol* 43:563–570
- Holtzman D, Khait I, Mulkern R, Allred E, Rand T, Jensen F, Kraft R (1999) In vivo development of brain phosphocreatine in normal and creatine-treated rabbit pups. *J Neurochem* 73:2477–2484
- Hosamani R, Ramesh SR, Muralidhara (2010) Attenuation of rotenone-induced mitochondrial oxidative damage and neurotoxicity in drosophila melanogaster supplemented with creatine. *Neurochem Res* 35:1402–1412
- Ireland Z, Russell AP, Wallimann T, Walker DW, Snow R (2009) Developmental changes in the expression of creatine synthesizing enzymes and creatine transporter in a precocial rodent, the spiny mouse. *BMC Dev Biol* 9:39
- Kang BP, Urbonas A, Baddoo A, Baskin S, Malhotra A, Meggs LG (2003) IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose. *Am J Physiol* 285:F1013–F1024
- Koga Y, Takahashi H, Oikawa D, Tachibana T, Denbow DM, Furuse M (2005) Brain creatine functions to attenuate acute stress responses through GABAergic system in chicks. *Neuroscience* 132:65–71
- Kovacic P, Thum LA (2005) Cardiovascular toxicity from the perspective of oxidative stress, electron transfer, and prevention by antioxidants. *Curr Vasc Pharmacol* 3:107–117
- Kuethle F, Krack A, Richartz BM, Figulla HR (2006) Creatine supplementation improves muscle strength in patients with congestive heart failure. *Die Pharmazie* 61:218–222
- Langen RC, Schols AM, Kelders MC, Van Der Velden JL, Wouters EF, Janssen-Heininger YM (2002) Tumor necrosis factor- $\alpha$  inhibits myogenesis through redox-dependent and -independent pathways. *Am J Physiol Cell Physiol* 283:C714–C721
- Lawler JM, Barnes WS, Wu G, Song W, Demaree S (2002) Direct antioxidant properties of creatine. *Biochem Biophys Res Commun* 290:47–52
- Lenz H, Schmidt M, Welge V, Schlattner U, Wallimann T, Elsasser HP, Wittern KP, Wenck H, Stab F, Blatt T (2005) The creatine kinase system in human skin: protective effects of creatine against oxidative and UV damage in vitro and in vivo. *J Invest Dermatol* 124:443–452
- Louis M, Van Beneden R, Dehoux M, Thissen JP, Francaux M (2004) Creatine increases IGF-I and myogenic regulatory factor mRNA in C2C12 cells. *FEBS Lett* 557:243–247
- Malatesta M, Perdoni F, Muller S, Pellicciari C, Zancanaro C (2010) Pre-mRNA processing is partially impaired in satellite cell nuclei from aged muscles. *J Biomed Biotechnol* 410405. Epub 2010 May 19
- Martinet W, de Meyer GR, Herman AG, Kockx MM (2004) Reactive oxygen species induce RNA damage in human atherosclerosis. *Eur J Clin Invest* 34:323–327
- Martinet W, De Meyer GR, Herman AG, Kockx MM (2005) RNA damage in human atherosclerosis: pathophysiological significance and implications for gene expression studies. *RNA Biol* 2:4–7
- Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF (1998) Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. *J Neurosci* 18:156–163

- Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. *Exp Neurol* 157:142–149
- Mazzini L, Balzarini C, Colombo R, Mora G, Pastore I, De Ambrogio R, Caligari M (2001) Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. *J Neurol Sci* 191:139–144
- McQuillen PS, Ferriero DM (2004) Selective vulnerability in the developing central nervous system. *Pediatr Neurol* 30:227–235
- Messina S, Altavilla D, Aguenouz M, Seminara P, Minutoli L, Monici MC, Bitto A, Mazzeo A, Marini H, Squadrito F, Vita G (2006) Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. *Am J Pathol* 168:918–926
- Meyer LE, Machado LB, Santiago AP, da-Silva WS, De Felice FG, Holub O, Oliveira MF, Galina A (2006) Mitochondrial creatine kinase activity prevents reactive oxygen species generation: antioxidant role of mitochondrial kinase-dependent ADP recycling activity. *J Biol Chem* 281:37361–37371
- Neubauer S, Remkes H, Spindler M, Horn M, Wiesmann F, Prestle J, Walzel B, Ertl G, Hasenfuss G, Wallimann T (1999) Downregulation of the Na(+)-creatine cotransporter in failing human myocardium and in experimental heart failure. *Circulation* 100:1847–1850
- Nunomura A, Hofer T, Moreira PI, Castellani RJ, Smith MA, Perry G (2009) RNA oxidation in Alzheimer disease and related neurodegenerative disorders. *Acta Neuropathol* 118:151–166
- Oliveira MS, Furian AF, Figuera MR, Fiorenza NG, Ferreira J, Rubin MA, Mello CF, Royes LF (2008) The involvement of the polyamines binding sites at the NMDA receptor in creatine-induced spatial learning enhancement. *Behav Brain Res* 187:200–204
- Olsen S, Aagaard P, Kadi F, Tufekovic G, Verney J, Olesen JL, Suetta C, Kjaer M (2006) Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. *J Physiol* 573:525–534
- Osbakken M, Ito K, Zhang D, Ponomarenko I, Ivanics T, Jahngen EG, Cohn M (1992) Creatine and cyclocreatine effects on ischemic myocardium: 31P nuclear magnetic resonance evaluation of intact heart. *Cardiology* 80:184–195
- Otten JV, Fitch CD, Wheatley JB, Fischer VW (1986) Thyrotoxic myopathy in mice: accentuation by a creatine transport inhibitor. *Metabolism* 35:481–484
- Persky AM, Brazeau GA (2001) Clinical pharmacology of the dietary supplement creatine monohydrate. *Pharmacol Rev* 53:161–176
- Rakpongsiri K, Sawangkoon S (2008) Protective effect of creatine supplementation and estrogen replacement on cardiac reserve function and antioxidant reservation against oxidative stress in exercise-trained ovariectomized hamsters. *Int Heart J* 49:343–354
- Rambo LM, Ribeiro LR, Oliveira MS, Furian AF, Lima FD, Souza MA, Silva LF, Retamoso LT, Corte CL, Puntel GO, de Avila DS, Soares FA, Figuera MR, Mello CF, Royes LF (2009) Additive anticonvulsant effects of creatine supplementation and physical exercise against pentylenetetrazol-induced seizures. *Neurochem Int* 55:333–340
- Reddy PH (2008) Mitochondrial medicine for aging and neurodegenerative diseases. *Neuromolecular Med* 10:291–315
- Represa A, Ben-Ari Y (2005) Trophic actions of GABA on neuronal development. *Trends Neurosci* 28:278–283
- Rochard P, Rodier A, Casas F, Cassar-Malek I, Marchal-Victorien S, Dauray L, Wrutniak C, Cabello G (2000) Mitochondrial activity is involved in the regulation of myoblast differentiation through myogenin expression and activity of myogenic factors. *J Biol Chem* 275:2733–2744
- Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA (2007) Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. *Muscle Nerve* 35:235–242
- Santiago AP, Chaves EA, Oliveira MF, Galina A (2008) Reactive oxygen species generation is modulated by mitochondrial kinases: correlation with mitochondrial antioxidant peroxidases in rat tissues. *Biochimie* 90:1566–1577
- Schedel JM, Tanaka H, Kiyonaga A, Shindo M, Schutz Y (1999) Acute creatine ingestion in human: consequences on serum creatine and creatinine concentrations. *Life Sci* 65:2463–2470
- Scholz A, Hinssen H (1995) Biphasic pattern of gelsolin expression and variations in gelsolin-actin interactions during myogenesis. *Exp Cell Res* 219:384–391
- Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, Falcieri E, Agostini D, Gioacchini AM, Stocchi V (2006) Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. *Free Radic Biol Med* 40:837–849
- Sestili P, Martinelli C, Ricci D, Fraternali D, Bucchini A, Giamperi L, Curcio R, Piccoli G, Stocchi V (2007) Cytoprotective effect of preparations from various parts of *Punica granatum* L. fruits in oxidatively injured mammalian cells in comparison with their antioxidant capacity in cell free systems. *Pharmacol Res* 56:18–26
- Sestili P, Barbieri E, Martinelli C, Battistelli M, Guescini M, Vallorani L, Casadei L, D'Emilio A, Falcieri E, Piccoli G, Agostini D, Annibalini G, Paolillo M, Gioacchini AM, Stocchi V (2009) Creatine supplementation prevents the inhibition of myogenic differentiation in oxidatively injured C2C12 murine myoblasts. *Mol Nutr Food Res* 53:1187–1204
- Sharov VG, Saks VA, Kupriyanov VV, Lakomkin VL, Kapelko VI, Steinschneider A, Javadov SA (1987) Protection of ischemic myocardium by exogenous phosphocreatine. I. Morphologic and phosphorus 31-nuclear magnetic resonance studies. *J Thorac Cardiovasc Surg* 94:749–761
- Sipila I, Rapola J, Simell O, Vannas A (1981) Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. *N Engl J Med* 304:867–870
- Stout JR, Eckerson JM, May E, Coulter C, Bradley-Popovich GE (2001) Effects of resistance exercise and creatine supplementation on myasthenia gravis: a case study. *Med Sci Sports Exerc* 33:869–872
- Tanaka M, Chock PB, Stadtman ER (2007) Oxidized messenger RNA induces translation errors. *Proc Natl Acad Sci USA* 104:66–71
- Tannu NS, Rao VK, Chaudhary RM, Giorgianni F, Saeed AE, Gao Y, Raghov R (2004) Comparative proteomes of the proliferating C(2)C(12) myoblasts and fully differentiated myotubes reveal the complexity of the skeletal muscle differentiation program. *Mol Cell Proteomics* 3:1065–1082
- Tarnopolsky MA (2007) Clinical use of creatine in neuromuscular and neurometabolic disorders. *Subcell Biochem* 46:183–204
- Tarnopolsky MA, Safdar A (2008) The potential benefits of creatine and conjugated linoleic acid as adjuncts to resistance training in older adults. *Appl Physiol Nutr Metabol Physiol Applique Nutr et Metabolisme* 33:213–227
- Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD, Biggar D (2004) Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. *Neurology* 62:1771–1777
- Tateyama M, Takeda A, Onodera Y, Matsuzaki M, Hasegawa T, Nunomura A, Hirai K, Perry G, Smith MA, Itoyama Y (2003) Oxidative stress and predominant Abeta42(43) deposition in myopathies with rimmed vacuoles. *Acta Neuropathol* 105:581–585
- Tokarska-Schlattner M, Wallimann T, Schlattner U (2002) Multiple interference of anthracyclines with mitochondrial creatine

- kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. *Mol Pharmacol* 61:516–523
- Toscano A, Messina S, Campo GM, Di Leo R, Musumeci O, Rodolico C, Aguenouz M, Annesi G, Messina C, Vita G (2005) Oxidative stress in myotonic dystrophy type 1. *Free Radic Res* 39:771–776
- Vexler ZS, Ferriero DM (2001) Molecular and biochemical mechanisms of perinatal brain injury. *Semin Neonatol* 6:99–108
- Vilquin JT (2005) Myoblast transplantation: clinical trials and perspectives. *Mini-Rev Acta Myol* 24:119–127
- Vorgerd M, Grehl T, Jager M, Muller K, Freitag G, Patzold T, Bruns N, Fabian K, Tegenthoff M, Mortier W, Luttmann A, Zange J, Malin JP (2000) Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. *Arch Neurol* 57:956–963
- Walzel B, Speer O, Zanolla E, Eriksson O, Bernardi P, Wallimann T (2002) Novel mitochondrial creatine transport activity Implications for intracellular creatine compartments and bioenergetics. *J Biol Chem* 277:37503–37511
- Weinstein DM, Mihm MJ, Bauer JA (2000) Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. *J Pharmacol Exp Ther* 294:396–401
- Witte KK, Clark AL, Cleland JG (2001) Chronic heart failure and micronutrients. *J Am Coll Cardiol* 37:1765–1774
- Wyss M, Kaddurah-Daouk R (2000) Creatine and creatinine metabolism. *Physiol Rev* 80:1107–1213
- Wyss M, Schulze A (2002) Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease? *Neuroscience* 112:243–260
- Yang S, Chintapalli J, Sodagum L, Baskin S, Malhotra A, Reiss K, Meggs LG (2005) Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination. *Am J Physiol* 289:F1144–F1152
- Young JF, Larsen LB, Malmendal A, Nielsen NC, Straadt IK, Oksbjerg N, Bertram HC (2010) Creatine-induced activation of antioxidative defence in myotube cultures revealed by explorative NMR-based metabolomics and proteomics. *J Int Soc Sports Nutr* 7:1–9